精华制药(002349) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥367,129,069.92, a decrease of 11.82% compared to ¥416,357,917.91 in the same period last year[5] - Net profit attributable to shareholders was ¥71,080,090.21, down 18.92% from ¥87,671,328.30 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0873, reflecting an 18.94% decline from ¥0.1077 in the same period last year[5] - Total operating revenue for the current period is ¥367,129,069.92, a decrease of 11.8% from ¥416,357,917.91 in the previous period[20] - Net profit for the current period is ¥81,983,042.72, a decline of 17.1% compared to ¥99,041,270.14 in the previous period[22] - The company reported a total profit of ¥95,867,429.67, down 17.5% from ¥116,172,239.12 in the previous period[22] Cash Flow and Investments - The net cash flow from operating activities increased significantly to ¥30,919,958.81, compared to a negative cash flow of ¥5,318,150.98 in the previous year, representing a 681.40% improvement[5] - Cash received from operating activities increased by 61.98% to CNY 13,437,527.22, primarily due to increased cash from subsidiary Dongli Chemical[9] - Cash recovered from investments dropped by 80.73% to CNY 10,000,000.00, attributed to higher redemptions of financial products in the previous year[9] - Investment income cash received fell by 81.57% to CNY 47,798.48, mainly due to lower returns from redeemed financial products compared to the previous year[9] - Investment activities resulted in a net cash outflow of ¥62,645,591.74, compared to a smaller outflow of ¥5,548,102.56 in the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,213,710,291.74, a slight increase of 0.90% from ¥3,185,011,365.95 at the end of the previous year[5] - Current assets totaled CNY 2,039,492,379.66, up from CNY 1,985,809,222.46 at the start of the quarter, indicating a growth of approximately 2.7%[17] - Total liabilities decreased to CNY 326,254,202.53 from CNY 380,746,462.33, a reduction of approximately 14.3%[18] - The equity attributable to shareholders rose to ¥2,516,644,496.19, marking a 2.95% increase from ¥2,444,593,197.18 at the end of the last year[5] - The equity attributable to the owners of the parent company increased to CNY 2,516,644,496.19 from CNY 2,444,593,197.18, reflecting a growth of about 2.9%[19] Income and Expenses - Total operating costs decreased to ¥278,288,740.26, down 6.8% from ¥298,578,026.85[20] - Financial expenses decreased significantly, with a reported amount of -¥10,177,062.05, indicating a 2923.92% change due to increased deposit income and reduced bank loan interest[8] - Other income increased by 309.45% to ¥4,180,842.03, primarily due to higher government subsidies received[8] - Research and development expenses increased to ¥17,109,278.74, up 29.5% from ¥13,215,026.76[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 129,620[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds a 34.39% stake with 279,994,660 shares[11] - The company has no preferred shareholders with restored voting rights at the end of the reporting period[11] - The total number of shareholders with priority shares was not applicable for this report period[16] Other Information - The company received government subsidies amounting to ¥2,943,257.89 during the quarter, contributing to its financial performance[6] - The company reported a significant increase in fair value gains of 216.42%, amounting to ¥2,866,682.19, attributed to favorable returns on financial products[8] - Tax refunds received decreased by 81.78% to CNY 160,334.05 due to increased input tax refunds and export tax rebates in the previous year[9] - Cash paid for the purchase of fixed assets increased by 83.69% to CNY 14,172,110.99, reflecting higher capital expenditures by subsidiary Senxuan Pharmaceutical[9] - Cash paid for other investment activities surged by 1168.44% to CNY 568,291.67, indicating increased cash outflows from the parent company[9] - The impact of exchange rate fluctuations on cash and cash equivalents was a negative CNY 1,838,051.23, a decrease of 147.65% due to changes in the USD exchange rate[9] - The company has not disclosed any new product developments or market expansion strategies in this quarter[16]